Sprint Bioscience AB (publ) (FRA:5JA1)

Market Cap	31.70M +368.4%
Revenue (ttm)	12.59M +133.9%
Net Income	6.83M
EPS	0.06
Shares Out	n/a
PE Ratio	4.42
Forward PE	13.71
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,000
Open	0.2810
Previous Close	0.3030
Day's Range	0.2810 - 0.2810
52-Week Range	0.0380 - 0.3850
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Oct 27, 2026

About Sprint Bioscience AB

Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of drug candidates to treat cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; DCPS which is in preclinical trial for the treatment of acute myeloid leukemia; VRK1, which is in preclinical development to treat solid tumors; VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; and NNMT for the treatment of solid tumors/chronic kidney diseases...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 32
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 5JA1

Financial Performance

Financial numbers in SEK

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error